Drug Pricing
Commentary
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
Commentary
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Commentary
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Commentary
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Commentary
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Commentary
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
Commentary
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
Commentary
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Commentary
Generics Must Compete On Price, Not Safety
America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
How innovation saves lives: What America’s pharmaceutical ecosystem gets right
When a woman is diagnosed with breast cancer in the United States today, her chances of surviving are much greater than in decades past — thanks to U.S. innovation. The incidence of breast cancer has increased by more than 200% globally in the past 40 years. But the U.S. mortality ...
What’s The GLP-1 Black Market, How Big a Threat Is It?
A black market in weight-loss drugs is flourishing in plain sight. Rogue pharmacies and telehealth firms are flooding the United States with unauthorized knock-offs of semaglutide, tirzepatide, and other glucagon-like peptide-1 drugs. Better known by brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, the knock-off versions of these drugs are ...
Generics Must Compete On Price, Not Safety
America’s generic drug market is one of our greatest health policy successes. Today, 91% of all prescriptions in the U.S. are filled with generics. That dominance saves patients and taxpayers hundreds of billions of dollars every year—and it also drives innovation. Drugmakers know their monopoly on a new treatment will ...
